Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J.P. Morgan Notebook: Tuesday January 14

This article was originally published in The Pink Sheet Daily

Executive Summary

Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the second day of the 2014 J.P. Morgan health care conference, including news from ZS Pharma, Aisling Capital, Astellas, and Moderna.

You may also be interested in...



Astellas Regains Japan Losses With Xtandi Expansion

Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.

Biopharma IPOs Start To Gear Up For 2013 After A Lull

Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel